Navigation Links
Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
Date:11/5/2007

- Results demonstrated 17% overall rate of sustained virologic response in

non-responders to previous interferon-based therapy - - SVR results in line with previous studies of long-acting interferons in

non- responders, with less frequent dosing - - Final data from Phase 2 Albuferon non-responder study presented at the Annual Meeting of the American Association for the Study of Liver Diseases

(AASLD) -

ROCKVILLE, Ma., Nov. 5 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the final results of a Phase 2 trial of the investigational drug, Albuferon(R) (albinterferon alfa-2b), in combination with ribavirin in patients with chronic hepatitis C who failed to respond to previous interferon-based therapy. The results were presented yesterday in Boston at the 58th AASLD Annual Meeting in Boston.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO )

"The results of the Albuferon non-responder study demonstrated that Albuferon treatment at doses up to 1800 mcg every two weeks had an acceptable long-term safety profile and produced an overall sustained virologic response (SVR) rate of 17% in these patients," said David Nelson, M.D., Associate Professor of Medicine, Medical Director of Liver Transplantation, and Chief of the Hepatobiliary Disease Section, University of Florida. "In the difficult to treat subgroup of genotype 1 chronic hepatitis C patients who previously failed to respond to treatment with pegylated interferon and ribavirin, Albuferon treatment produced an overall SVR rate of 11%."

In the open-label,
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... enrollment in its first Phase 2a study, RXI-109-1301.  ... the 1-month findings that were reported in September ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "MEMS Gyroscopes Analog Devices ADIS16136 Precision ... to their offering. ... grade applications made a lot of progress in ... They are now accepted in high-reliability environments, and ...
(Date:12/15/2014)... 2014 BerGenBio AS, a biopharmaceutical ... resistant cancers, today announces that it has raised NOK90 ... new and existing investors. BerGenBio will use ... of its pipeline of innovative cancer therapeutics, in particular ... candidate, BGB324, a first-in-class selective Axl kinase inhibitor, which ...
Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2BerGenBio Completes NOK90 Million Fundraising 2
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced ... of Directors.  Dr. McKinnell is the former Chief Executive ... of Pfizer Inc.  He is currently Chairman of the ... infectious diseases in Africa, and is a member of ...
... and NEW YORK, Jan. 10, 2011 Resolvyx Pharmaceuticals ... Celtic Therapeutics ), a successor firm to Celtic Pharma, ... agreement under which Celtic Therapeutics has acquired and licensed ... for the treatment of dry eye syndrome and other ...
Cached Medicine Technology:Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors 2Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors 3Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors 4Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology 2Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology 3Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology 4
(Date:12/17/2014)... parents should leave prenatal picture-taking to medical professionals, the ... ultrasound imaging and heartbeat monitors to get "keepsake" images ... "Although there is a lack of evidence ... monitors, prudent use of these devices by trained health ... engineer, said in an agency news release. "Ultrasound ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 ... overall health, but a growing body of evidence shows the ... finds. In fact, the benefits were similar to those ... Paula Chu, a doctoral candidate at Harvard University,s Health Policy ... found that people randomly assigned to take yoga classes saw ...
(Date:12/15/2014)... 2014 Veretekk.com, Inc. announced today a ... JM Ocean Avenue has secured exclusive benefit to ... marketing system. JM Ocean Avenue is a direct ... Ocean Avenue and JM International, with partial ownership coming ... year company. , “After nearly 2 decades of servicing ...
(Date:12/15/2014)... 2014 OutMarket , a provider ... Social Media Cheat Sheets ,” a guide that exposes ... results on the top ten social media networks. ... drive awareness, engagement, and customer service. It can also ... an impact on new networks and weather constantly changing ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss in the ... contributing to the growth in the global audiological market. Devices ... loss and balance disorders are known as audiological devices. An ... amplifier. The global market is expected to grow at a ... 2014 to 2019. Some of the factors which are driving ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... recent tests conducted by the Analytical Services Tasmania King Island's ... Greens conducted tests which showed high content of lead in ... by testing done by the council which found no problem ... heavy metals and the results were announced with days of ...
... by the investigators at John Hopkins Children’s Center//, patient’s safety ... the medication errors into a computer database. ... fixing and reporting on the errors voluntarily plus steps taken ... systems are not new, but few studies have looked at ...
... the end of last year, surgeons from Australia had performed ... Royal Prince Alfred Hospital had carried out the surgery on ... South Wales. Leanne Myles was reported to be on her ... pancreas. ,She was diagnosed when she was 19, ...
... held at Varca in Goa it is found that ... levels. //The two day conference mainly analyzed the ... to hyperhomocysteinemia. This would further worsen the situation by ... heart attack, diabetes and other fatal diseases. Experts and ...
... education to youngsters is important to tackle HIV/AIDS in ... // ,Engaging youngsters and giving them leadership ... necessary, Micheal Friedman of Centre for Disease Control of ... Madras Medical Mission., ,Clinical commitment, expertise in treatment ...
... United Nations has sounded alarm over rising cocaine consumption ... rise again in Afghanistan this year reversing the decline ... report, the world body urged European Union governments not ... use cocaine, often denying their addiction, and drug abuse ...
Cached Medicine News:Health News:Voluntary Error-Reporting System Ensures Patient Safety 2Health News:Voluntary Error-Reporting System Ensures Patient Safety 3Health News:Voluntary Error-Reporting System Ensures Patient Safety 4
CUSA DISSECTRON PORTABLE UNIT is an ultrasonic surgical aspirator for the fragmentation and emulsification of tissue available only outside the United States....
The Nevyas Drape Support is the simple and inexpensive way to establish a zone of comfort for your patients during ophthalmic surgery which requires draping over the nose and mouth. Packaged in sets ...
This is a 2.5x focusing Galilean telescope with a range from 70cm to infinity. Ideal for use at sporting events, as well as for a wide range of hobbies....
... Hi-Mag takes us to the practical ... magnifier is often a 'last resort' ... visual acuities. The illuminated housing ensures ... to the battery handle by a ...
Medicine Products: